.svg)
.png)
___________
RTSM implementations have traditionally followed a fairly rigid and sequential process: sponsors and RTSM teams spend a lot of time defining requirements on paper, those requirements are translated into configuration layered as needed with custom code, and the first meaningful look at the system usually happens only after development is complete. It’s an approach that works, but it often leads to long timelines, multiple cycles of clarification, and the occasional disconnect between what the study team intended and how the RTSM actually functions.
Instead of the traditional model where requirements and system build happen in separate phases, Elosity allows both to occur in tandem. Its guided design interface and configurability let Endpoint Business Solutions Architects build the RTSM directly as they review the protocol. This means sponsors are seeing the in-progress build much earlier, often beginning at the very first design discussions, and the entire process becomes more collaborative, transparent, and aligned with how study teams actually think about their workflows.
In a standard RTSM build, most of the early effort focuses on translating the protocol into detailed requirements documents. These documents are essential, but they can introduce challenges, especially when different teams interpret details slightly differently or when a concept makes sense on paper but looks or behaves differently once it’s in the RTSM. That dynamic can slow things down, and in some cases, it forces teams to revisit decisions later in the implementation process.
Elosity shifts this dynamic by letting teams see the RTSM as it’s being built. The Endpoint Business Solutions Architect works directly within a step-by-step configuration flow, and as foundational elements like treatment arms, kit types, initial cohorts, and study-specific data elements are defined, they naturally feed into later components such as visit schedules, transactions, and dispensation rules. The result is that decisions are grounded in how the system will actually function, not just how they sound in a document.
One of the biggest advantages of this approach is that study teams get to interact with the RTSM much earlier than they’ve been able to in the past. They aren’t just reviewing text descriptions of what the system will do; they can actually see it, either through design interface visualizations or through the Live Preview, which reflects a fully functioning version of the study as it’s being configured.
As the build progresses, sponsors can receive read-only access to the development environment. With dummy kits and randomization lists loaded, teams can walk through complete patient and inventory workflows, view the system from multiple user roles, and understand how blinding and role-based access configurations are operating. This level of early visibility leads to much clearer decision making, better alignment across teams, and more effective preparation for UAT.
Because Elosity is configuration-based, the reliance on technical development resources is significantly reduced. The Business Solutions Architect manages the end-to-end build using the guided interface, which simplifies design conversations and removes many of the layers that typically exist in custom-coded RTSM implementations. What would normally require going back to technical teams to scope, code, and test can often beconfigured and reviewed live in a session.
This same benefit applies to study integrations. Elosity’s Integration Marketplace contains a library of integrations that are built once, validated, and made available for configuration across studies. It removes a tremendous amount of friction by avoiding customized integration builds each time and gives study teams a clear, consistent approach to connecting RTSM with systems like EDC, inventory management, temperature excursion monitoring, forecasting, and ePRO/eCOA.
Protocol amendments are a reality for almost every trial, and they’ve historically been one of the most time-consuming parts of RTSM maintenance. Elosity’s configuration driven approach and built-inversion control significantly improve this experience. Production versions can be brought back into the development environment without interrupting on oing study operations, updated using the same guided configuration interface used in the initial build, and reviewed with complete transparency. Because changes don’t require new code, even for integration modifications, amendment timelines shift from months to days or weeks, depending on the complexity of the update.
This makes the amendment process more predictable and far less disruptive for sponsors and operational teams.
It’s worth noting that Elosity wasn’t built in a vacuum. Endpoint’s team has more than 15 years of experience delivering RTSM solutions across thousands of trials, and that experience directly shaped the platform. The same people who influenced the design of Elosity - the ones who understand the nuance of randomization, supply strategy, operational workflows, and integrations - are the ones guiding study teams through implementation.
This combination of sophisticated tools and experienced people is what allows the agile model to really work. The platform provides the flexibility, transparency, and speed, and the team ensures every design decision is grounded in RTSM best practices and alignedwith the study’s needs.
Elosity brings together configuration-based design, real-time system visibility, reusable integrations, and a far more agile amendment process. Study teams understand their system earlier, make decisions with greater clarity, and move through the build and amendment cycles more efficiently, all while reducing reliance on technical teams.
For modern clinical trials, especially those with adaptive components or evolving protocols, this level of agility isn’t just helpful. It’s essential.
If you’re preparing for an upcoming study and want a more interactive and flexible RTSM experience, we’d be glad to show you how Elosity can support your goals.
A Next Generation Approach to Study Design and Delivery
Agentic AI as a Catalyst for Clinical Innovation
Explore how PULSE® is redefining RTSM with speed, flexibility, and AI-powered insights.
